Functional validation of genes implicated in lymphomagenesis: An in vivo selection assay using a Myc-induced B-cell tumor

Annals of the New York Academy of Sciences

Volumn 1059, Issue , 2005, Pages 145-159

  Yu, Duonan ^a   Cozma, Diana ^a   Park, Andrea ^a   Thomas Tikhonenko, Andrei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell lymphoma; c Myc; IL10; Mcl1; Target genes

Indexed keywords

4 HYDROXYTAMOXIFEN; INTERLEUKIN 10 RECEPTOR; MYC PROTEIN; PROTEIN MCL 1; PROTEIN P53; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; B CELL LYMPHOMA; BONE MARROW CELL; CARCINOGENESIS; CELL SELECTION; CONFERENCE PAPER; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE INACTIVATION; GENE TARGETING; GENE THERAPY; HEMATOPOIETIC CELL; IN VIVO STUDY; LYMPHOMA; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE MYC; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ANIMALIA; MURINAE;

EID: 32244437837     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1339.047     Document Type: Conference Paper

References (33)

1. EILERS, M., D. PICARD, K.R. YAMAMOTO & J.M. BISHOP. 1989. Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340: 66-68.
2. MATEYAK, M.K., A.J. OBAYA, S. ADACHI & J.M. SEDIVY. 1997. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth & Differentiation 8: 1039-1048.
3. JOHNSTON, L.A., D.A. PROBER, B.A EDGAR, et al. 1999. Drosophila myc regulates cellular growth during development. Cell 98: 779-790.
4. TRUMPP, A., Y. REFAELI, T. OSKARSSON, et al. 2001. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 414: 768-773.
5. HERMEKING, H., C. RAGO, M. SCHUHMACHER, et al. 2000. Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA 97: 2229-2234.
6. WANG, J., L.Y. XIE, S. ALLAN, et al. 1998. Myc activates telomerase. Genes Dev. 12: 1769-1774.
7. MITCHELL, K.O. & W.S. EL-DEIRY. 1999. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 10: 223-230.
8. CLAASSEN, G.F. & S.R. HANN. 2000. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc. Natl. Acad. Sci. USA 97: 9498-9503.
9. CARTEL, A.L., X. YE, E. GOUFMAN, et al. 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. USA 98: 4510-4515.
10. SEOANE, J., C. POUPONNOT, P. STALLER, et al. 2001. TGF influences Myc, Miz-1 and Smad to control the CDK inhibitor p 15INK4b. Nature Cell. Biol. 3: 400-408.
11. STALLER, P., K. PEUKERT, A. KIERMAIER, et al. 2001. Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell. Biol. 3: 392-399.
12. MARHIN, W.W., S. CHEN, L.M. FACCHINI, et al. 1997. Myc represses the growth arrest gene gadd45. Oncogene 14: 2825-2834.
13. OSTER, S.K., C.S. HO, E.L. SOUCIE & L.Z. PENN. 2002. The myc oncogene: marvelously complex. Adv. Cancer Res. 84: 81-154.
14. O'CONNELL, B.C., A.F. CHEUNG, C.P. SIMKEVICH, et al. 2003. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 278: 12563-12573.
15. PATEL, J.H., A.P. LOBODA, M.K. SHOWE, et al. 2004. Analysis of genomic targets reveals complex functions of MYC. Nat. Rev. Cancer 4: 562-568.
16. YU, D., M. DEWS, A. PARK, et al. 2005. Inactivation of Myc in two-hit B-lymphomas causes dormancy with elevated levels of interleukin-10 receptor and CD20: implications for adjuvant therapies. Cancer Res. 65: 5454-5461.
17. YU, D. & A. THOMAS-TIKHONENKO. 2002. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21: 1922-1927.
18. YU, D., D. ALLMAN, M. GOLDSCMIDT, et al. 2003. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101: 1950-1955.
19. PEAR, W.S., J.P. MILLER, L. XU, et al. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
20. LITTLEWOOD, T.D., D.C. HANCOCK, P.S. DANIELIAN, et al. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23: 1686-1690.
21. KUPPERS, R. 2005. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5: 251-262.
22. WEIH, F. & J. CAAMANO. 2003. Regulation of secondary lymphoid organ development by the nuclear factor-κB signal transduction pathway. Immunol. Rev. 195: 91-105.
23. PACKHAM, G. & F.K. STEVENSON. 2005. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114: 441-449.
24. MOORE, K.W., M.R. DE WAAL, R.L. COFFMAN & A. O'GARRA. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
25. ROUSSET, F., E. GARCIA, T. DEFRANCE, et al. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89: 1890-1893.
26. HUANG, S., K. XIE, C.D. BUCANA, et al. 1996. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 2: 1969-1979.
27. SILVESTRE, J.S., Z. MALLAT, M. DURIEZ, et al. 2000. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ. Res. 87: 448-452.
28. CERVENAK, L., L. MORBIDELLI, D. DONATI, et al. 2000. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 96: 2568.
29. KUHN, R., J. LOHLER, D. RENNICK, et al. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
30. GAMERO, A.M., H.A. YOUNG & R.H. WILTROUT. 2004. Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 5: 111-112.
31. BUETTNER, R., L.B. MORA & R. JOVE. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8: 945-954.
32. HO, A.S., Y. LIU, T.A. KHAN, et al. 1993. A receptor for interleukin 10 is related to interferon receptors. Proc. Natl. Acad. Sci. USA 90: 11267-11271.
33. NIU, G., R. HELLER, R. CATLETT-FALCONE, et al. 1999. Gene therapy with dominant-negative StatS suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59: 5059-5063.